A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

Study acronym: UP-RISING
StatusRecruiting
PhaseNot specified
SponsorAbbVie
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 72 → 75 locations
    • Eligibility criteria expanded, about 6 words
  2. Trial sites expanded: 53 → 72 locationsv11
  3. Study sites: 52 to 53v10
  4. Study sites: 45 to 52v9
  5. Study sites: 42 to 45v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 39 to 42v7
  2. Study sites: 29 to 39v6
  3. Study sites: 19 to 29v5
  4. Study sites: 14 to 19v4
  5. Study sites: 8 to 14v3
  6. Study sites: 6 to 8v2
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AbbVie
349 trials monitored
See 27 trials at risk
Rheumatoid Arthritis
663 trials monitored
See 15 trials at risk
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or TNFi therapy. Around 678 participants will be enrolled in approximately 80 sites in Germany. Study recruitment will last approximately 24 months, and the study participation time will be up to 24 months, for a total study duration of approximately 48 months.
Trial Details
NCT Number NCT06712628
Lead Sponsor AbbVie
Conditions
(from sponsor)		 Moderate to Severe Rheumatoid Arthritis
Related terms Arthritis, Rheumatoid
Enrollment 678 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov